Contemporary management of peripheral arterial disease: II. Improving walking distance and quality of life

Cleveland Clinic Journal of Medicine

Volumn 73, Issue SUPPL.4, 2006, Pages 38-44

  Carman, Teresa L ^a   Fernandez, Bernardo B ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXERCISE; HUMAN; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PHYSIOLOGY; QUALITY OF LIFE; REVIEW; WALKING;

EXERCISE; HUMANS; PERIPHERAL VASCULAR DISEASES; QUALITY OF LIFE; WALKING;

EID: 34247590371     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.Suppl_4.S38     Document Type: Article

References (38)

1. Clanton TL, Klawitter PF. Invited review: adaptive responses of skeletal muscle to intermittent hypoxia: the known and the unknown. J Appl Physiol 2001; 90:2476-2487.
2. McCombs PR, Subramanian S. The benefits of exercise in intermittent claudication: effects on collateral development, circulatory dynamics and metabolic adaptations. Ann Vasc Surg 2002; 16:791-796.
3. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA 1995; 274:975-980.
4. Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. Sports Med 2004; 34:983-1003.
5. McDermott MM, Liu K, Ferrucci L, et al. Physical performance inperipheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006; 144:10-20.
6. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006; 113:e463-e654.
7. Jacoby D, Mohler III ER. Drug treatment in intermittent claudication. Drugs 2004; 64:1657-1670.
8. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18:1942-1947.
9. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90:1314-1319.
10. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87(Suppl):28D-33D.
11. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38:710-713.
12. Windmeier C, Gressner AM. Pharmacologic aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrosis. Gen Pharmacol 1997; 29:181-196.
13. Regensteiner JG, Ware Jr JE, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50:1939-1946.
14. Dean SM. Pharmacologic treatment for intermittent claudication. Vasc Med 2002; 7:301-309.
15. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109:523-530.
16. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996; 155:1053-1059.
17. Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999; 178:141-146.
18. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92:711-712.
19. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114:359-364.
20. Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108:1481-1486.
21. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107:757-761.
22. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96(Suppl):24F-33F.
23. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Ramipril markedly improves walking ability in patients with peripheral arterial disease. Ann Intern Med 2006; 144:660-664.
24. Morishita R, Aoki M, Ogihara T. Does gene therapy become pharmacotherapy? Exp Physiol 2005; 90:307-313.
25. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet, 2002; 359:2053-2058.
26. Hiatt WR. Carnitine and peripheral arterial disease. Ann NY Acad Sci 2004; 1033:92-98.
27. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001; 110:616-622.
28. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc 2001; 33:1415-1422.
29. Oka RK, Szuba A, Giacomini JC, Cooke JP. A pilot study of Larginine supplementation on functional capacity in peripheral arterial disease. Vasc Med 2005; 10:265-274.
30. Gornik HL, Creager MA. Arginine and endothelial and vascular health. J Nutr 2004; 134(10 Suppl):2880S-2887S.
31. Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 2005; 56:409-415.
32. Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication. Circulation 2000; 102:426-431.
33. Mohler ER III, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue. J Am Coll Cardiol 2003; 41:1679-1686.
34. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159:337-345.
35. Nylænde M, Kroese A, Stranden E, et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006; 11:21-28.
36. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29:439-493.
37. Olin JW, Hiatt WR, Mohler E, et al. A multicenter, randomized, double-blind, placebo-controlled study of immune modulation therapy in patients with symptomatic peripheral arterial disease: the SIMPADICO trial. Late-breaking oral presentation at the 55th Annual Scientific Session of the American College of Cardiology; March 13, 2006; Atlanta, GA.
38. Dawson DL. Comparative effects of cilostazol and other therapies for intermittent claudication. Am J Cardiol 2001; 87(Suppl), 19D-27D.